Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner
暂无分享,去创建一个
Hong Wang | Jian Ding | Xinyi Liu | Ligong Lu | Jingwei Jiang | Meixiao Zhan | S. Yuan | Li Sun | Pengcheng Ma | Hongzhi Du | Yao Wu | Dezhen Peng | Peng Chen | Danyu Du | Xingxv Huang
[1] A. Hale,et al. Nitric Oxide Modulates Metabolic Remodeling in Inflammatory Macrophages through TCA Cycle Regulation and Itaconate Accumulation , 2019, Cell reports.
[2] Ya-ping Tang,et al. A novel GTPCH deficiency mouse model exhibiting tetrahydrobiopterin-related metabolic disturbance and infancy-onset motor impairments. , 2019, Metabolism: clinical and experimental.
[3] Eugene E. Kwan,et al. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML , 2019, Nature Chemical Biology.
[4] D. Geerts,et al. Anti‐tumor effect of sulfasalazine in neuroblastoma , 2019, Biochemical pharmacology.
[5] E. McNeill,et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer , 2018, Nature.
[6] R. Deberardinis,et al. Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. , 2018, Cell metabolism.
[7] LaKesla R Iles,et al. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability , 2018, Clinical Cancer Research.
[8] Yaoyong Li,et al. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia , 2018, Cell reports.
[9] K. Takayama,et al. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer , 2018, Oncogene.
[10] B. Singh,et al. BH3-only protein BIM: An emerging target in chemotherapy. , 2017, European journal of cell biology.
[11] N. Perrimon,et al. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. , 2017, Cancer cell.
[12] Min Huang,et al. Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity , 2017, Oncogene.
[13] Jun-jie Yu,et al. DT-13 synergistically enhanced vinorelbine-mediated mitotic arrest through inhibition of FOXM1-BICD2 axis in non-small-cell lung cancer cells , 2017, Cell Death and Disease.
[14] X. Hou,et al. DT-13 inhibits cancer cell migration by regulating NMIIA indirectly in the tumor microenvironment. , 2016, Oncology reports.
[15] D. Geerts,et al. Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target , 2015, BMC Cancer.
[16] K. Channon,et al. Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway , 2015, Neuron.
[17] D. Laskin,et al. Sulfa Drugs Inhibit Sepiapterin Reduction and Chemical Redox Cycling by Sepiapterin Reductase , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[18] Junbo Hu,et al. Threonine 32 (Thr32) of FoxO3 is critical for TGF-β-induced apoptosis via Bim in hepatocarcinoma cells , 2014, Protein & Cell.
[19] D. Geerts,et al. Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation. , 2014, Journal of molecular biology.
[20] K. Johnsson,et al. Tetrahydrobiopterin Biosynthesis as an Off-Target of Sulfa Drugs , 2013, Science.
[21] D. Laskin,et al. Sepiapterin Reductase Mediates Chemical Redox Cycling in Lung Epithelial Cells* , 2013, The Journal of Biological Chemistry.
[22] E. Werner,et al. Alkylglycerol Monooxygenase , 2013, IUBMB life.
[23] P. Galle,et al. Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells , 2012, British Journal of Cancer.
[24] N. Blau,et al. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia , 2012, Journal of Inherited Metabolic Disease.
[25] P. Ward,et al. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.
[26] K. Aldape,et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.
[27] Myoung-Dong Kim,et al. Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70S6K-dependent VEGFR-2 expression. , 2011, Oncology reports.
[28] E. Werner,et al. Tetrahydrobiopterin: biochemistry and pathophysiology. , 2011, The Biochemical journal.
[29] K. Johnsson,et al. A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. , 2011, Nature chemical biology.
[30] D. Kerr,et al. Roles of tetrahydrobiopterin in promoting tumor angiogenesis. , 2010, The American journal of pathology.
[31] F. Tarazi,et al. Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-/- mice: relevance to schizophrenia. , 2010, BMB reports.
[32] P. Choong,et al. Bim-targeted cancer therapy: A link between drug action and underlying molecular changes , 2009, Molecular Cancer Therapeutics.
[33] G. Wildey,et al. Runx1 Is a Co-activator with FOXO3 to Mediate Transforming Growth Factor β (TGFβ)-induced Bim Transcription in Hepatic Cells* , 2009, The Journal of Biological Chemistry.
[34] Nenad Blau,et al. Mutations in the BH4‐metabolizing genes GTP cyclohydrolase I, 6‐pyruvoyl‐tetrahydropterin synthase, sepiapterin reductase, carbinolamine‐4a‐dehydratase, and dihydropteridine reductase , 2006, Human mutation.
[35] N. Blau,et al. Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. , 2001, Molecular genetics and metabolism.
[36] M. Edelstein,et al. New inhibitors of sepiapterin reductase. Lack of an effect of intracellular tetrahydrobiopterin depletion upon in vitro proliferation of two human cell lines. , 1992, The Journal of biological chemistry.
[37] R. Deberardinis,et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.